Hormonal
Withholding GLP-1 receptor agonists for at least three half-lives before elective surgery is recommended for weight management patients to minimize retained gastric contents.
For weight loss patients: Check the half-life of your specific drug (e.g., Semaglutide ~7 days, Dulaglutide ~5 days). Stop taking it at least 3 times that duration before your scheduled surgery. For example, if you take Semaglutide (7-day half-life), stop at least 21 days before surgery. Consult your doctor for a bridge plan for blood sugar if applicable.
For patients taking glucagon-like peptide-1 receptor agonists for weight management, these drugs should be withheld for at least three half-lives before an elective surgical procedure.
Why this rating
Based on pharmacokinetic data and observational evidence of gastric emptying, but no RCTs on optimal withholding times.
Source
Glucagon‐like peptide‐1 receptor agonists: a narrative review of clinical pharmacology and implications for peri‐operative practice
David A. Milder et al. · Anaesthesia · 2024
DOI 10.1111/anae.16306
More from this paper
- GLP-1 receptor agonists delay gastric emptying and increase the risk of pulmonary aspiration during general anesthesia, necessitating specific peri-operative management strategies.Moderate
- For patients with Type 2 Diabetes, prolonged cessation of GLP-1 receptor agonists may worsen peri-operative glycaemic control, requiring individualized management and endocrinologist consultation.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →